APIS Assay Technologies Limited
A £3m loan facility from the GMCA, alongside a £21m investment from Manchester City Council was approved for APIS Assay Technologies, in support of the creation of a world-leading precision medicine campus in the Corridor Manchester Enterprise Zone.
The joint project with global diagnostics firm QIAGEN, is forecast to create and support up to 1,500 jobs and add £140m to Greater Manchester's economy over a decade.
This project will anchor the life sciences sector in GM, by attracting related small and medium-sized enterprises to the Applied Health Innovation Campus, attracting and retaining university graduates, and reinforcing the city’s reputation at the cutting edge of innovation. The development of new diagnostic tests aimed at earlier detection of disease, and the development of personalised treatments, will also benefit the residents of Greater Manchester.